Treace Medical Concepts Unveils Fourth Quarter and Full-Year 2025 Financial Results on February 27, 2026

Medical device innovator Treace Medical Concepts, Inc. (NasdaqGS: TMCI) announced that it will release its comprehensive financial results for the fourth quarter and full year of 2025 on February 27, 2026, before market opening. This strategic disclosure comes as the company continues to advance surgical solutions for bunion treatment and related midfoot correction procedures. The company’s leadership team will host an investor discussion beginning at 8:00 am ET, providing stakeholders with insights into the company’s operational and financial performance.

Registered participants can access the conference call by receiving dial-in information and a unique identification pin following enrollment. A live webcast and permanent recording of the event will be accessible through Treace’s investor relations portal at the company’s website, ensuring transparent communication with all interested parties.

Pioneering Surgical Innovation for Bunion Correction

Treace has established itself as a leader in addressing complex midfoot deformities affecting approximately 67 million Americans. The company estimates that approximately 1.1 million patients annually represent candidates for surgical intervention. The company’s flagship Lapiplasty 3D Bunion Correction System represents a breakthrough in surgical methodology, combining specialized instruments, implants, and innovative techniques to address all three dimensions of bunion deformities while stabilizing the underlying joint structure.

This three-dimensional approach fundamentally differs from traditional methods by targeting the root cause of bunion development rather than merely addressing surface symptoms. The Lapiplasty system has enabled surgeons to help patients return to active lifestyles with improved outcomes and enhanced quality of life.

Comprehensive Product Solutions Across Correction Techniques

Beyond its core offering, Treace has developed a robust portfolio addressing diverse surgical needs. The Adductoplasty Midfoot Correction System provides reproducible surgical outcomes for complex midfoot deformities. The company offers two specialized systems for minimally invasive osteotomy procedures: the Nanoplasty 3D Minimally Invasive Bunion Correction System and the Percuplasty Percutaneous 3D Bunion Correction System, which utilizes percutaneous pinning techniques for enhanced precision.

Additionally, Treace markets the SpeedMTP System for alternative applications and continues expanding its rapid compression implant platform—the SpeedPlate system—into new clinical indications. The company’s digital ecosystem, featuring IntelliGuide patient-specific pre-operative planning and surgical cut guide technology, represents the integration of advanced computational solutions into surgical practice, enabling surgeons with data-driven precision tools.

Staying Connected with Investor Relations

Treace maintains an active Investor Relations section on its corporate website, where the company regularly posts material updates and announcements relevant to shareholders and potential investors. The company strongly encourages market participants to monitor these communications for timely updates regarding company developments and strategic initiatives.

Contacts: Treace Medical Concepts Mark L. Hair Chief Financial Officer

Investor Relations: Gilmartin Group Philip Trip Taylor